PROTEINATOR is the first version of a staggered, multi-paradigm and extensible drug repurposing platform, focusing on a novel data analytic and integration strategy to find repurposing candidates that have potential to modulate targets through protein-protein interactions. The UI was created as an explorer to find 'indirect' drugs for a protein of interest. PROTEINATOR is developed as a web application that lets researchers search for alternate drugs for a protein of interest, based on the protein's direct interaction with a another druggable protein.
integration.
Introduction
Systematic drug repurposing is the re-evaluation of known, pharmaceutically relevant compounds towards identifying new indications ( (Papapetropoulos and Szabo, 2018) ). Analogously, therapeutic switching of known drugs mitigates protracted in vitro and in vivo screening, chemical optimization, toxicology studies, bulk manufacturing and clinical trials ((Csermely et al., 2013) ). PRO-TEINATOR provides a novel method to do both based on a compound's ability to modulate the function of the protein of interest, which is in turn, an interacting partner of the compound's primary target. It is a tool that provides an annotated list of drug repurposing candidates, where the mechanism of action is closely related to protein-protein interactions (PPI) . Nonetheless, it should be noted that it provides a list of indirect interactions that may or may not result in the inhibition of action of the protein of interest and limited to inhibiting functions that are dependent on the interacting protein (the direct binding partner of the drug). It is highly plausible to find many useful interactions that can be exploited to reposition drugs, altough it is not an automated system of enquiry -it takes scientists' intuition and/or cycles of validation to reach novel repurposing hypothesis. While it is not feasible to try and validate all >100 thousand interactions that we have found, we have presented 7 such cases where experimental validation is present in previous literature. This goes to prove that unexplored possibilities exist, to find new interactions of value using this methodology through our tool.
Given a protein(s) of interest, like those being closely associated with a disease phenotype, we provide a list of leads that may indirectly modulate the function of this target protein through a protein-protein interaction (PPI). Newly identified leads may be pursued as inhibitors to proteins that did not have any known binders, or as alternate drugs that may help overcome individualized drug resistance issues. The interactions are retrieved from iRefWEb and 2 STRING ( (Turner et al., 2010 , Szklarczyk et al., 2015 ) , and filtered using dataassisted integrative analysis sourced from heterogeneous databases (see Figure   1 ). It is ensured that both proteins of valid PPIs that constitute search hits in PROTEINATOR are co-expressed in at least one common tissue, and members in a common biological pathway. Large-scale multi-omics projects have identified coordinated expression patterns of proteins based on tissue type (a list and summary in Sulakhe et al.((Sulakhe et al., 2018) )). PROTEINATOR uses these contextual co-localizations of interacting proteins as a condition to identify candidate PPIs. Specifically, we use TISSUES ( ) data and confidence score to filter interactions based on co-expression within specific tissues. Molecular pathways represent a defined function that are coordinated by a specific set of proteins. We also filter based on whether the two proteins are present in at least one common pathway based on data from BioSystems ((Geer et al., 2010) ).
The input to the tool is a target protein(s), and the result are a set of interacting partner-proteins with the repurposing candidate drugs (associated to the partner-proteins). Currently, the manually curated database, DrugBank Wishart et al. ((2017) ) is used to identify all drug-protein associations. Succintly, PROTEINATOR assists in generating a plausible list of repurposing hypotheses using PPIs as a central theme.
Drug repurposing through data integration
Given the existence of high quality data from X-omic (genomics, proteomics, transcriptomics, etc.) and other experimental studies that originate from leading institutes exist in silos, many prominent questions of diagnostic and pharmocological value (like fishing for repurposing hyopothesis based on a filtered set of PPI) can only be answered by serially querying multiple databases. Since the databases originate from different sources, it will entail multiple ID mapping of common entities, and most likely, human intervention even to compile all hits that constitute a result. Web UIs, like PROTEINATOR, are critical towards providing non-computational scientists capabilities to probe complex questions that require navigating multiple databases ((Sam and Athri, 2017) ).
PROTEINATOR is a unique hypotheses generating platform that provides coordinated access to multiple databases to systematically search for repurposing candidates that are PPI modulators through a user-friendly UI (see Supple- mentary Material (S.2) for other web tools that explore PPI-small molecule interactions).
Targeting PPIs to mine repurposing candidates
Protein-protein interactions (PPI) form the basis of large biological networks that effectuate nearly all biological processes. While interactions that constitute a particular pathway result in a final product, networks are just interconnected proteins that can be visualized as nodes and edges of a graph ( (Bonetta, 2010) ) and carry out a variety of intra-cellular and extra cellular activities. The human PPI network (interactome) comprises somewhere between 400,000 to 630,000 interactions( (Petta et al., 2016 , Venkatesan et al., 2009 , Stumpf et al., 2008 ) , which represents a ubiquitous, unexplored cache of potential targets as compared to other individual macromolecular targets. Currently, there are only 50 PPIs that are known to be modulated by small molecules ((Higueruelo et al., 2013a) ), indicative of an unexplored druggable dimension that can potentially be used to discover specific targets to cure all diseasesSkwarczynska and Ottmann ((2015) ). It has been noted( (Arkin and Wells, 2004) ) that there is a dearth of natural start points to begin drug design initiatives involving small molecules to modulate PPIs, and is one of important reasons it is referred to as targeting the 'high hanging fruit' ( (Wells and McClendon, 2007) ). While it is apparent that this class of targets has the largest regulatory impact on biological processes and hence on the onset of disease states, and that there have been numerous clinic trials of small molecule binders specifically targeting them, there are no web-based tools available to drug design groups to explore plausible repurposing candidates from putative drugs in early or late stage of drug discovery. PROTEINATOR is a unique hypotheses generating platform that provides novel filters that increase the probability of finding valid repurposing 4 candidates that are PPI modulators. In the past decade or so, researchers have developed a variety of experimental and computational methods to search and validate druggable PPIs, and we seek to provide a user-friendly interface to explore chemicals that may modulate PPIs, based on their interaction with one of the protein partners. The list of hypotheses produced by PROTEINATOR may then be validated further using both experimental and computational techniques (for reviews on methods to explore PPI as targets for small molecule drug design see ( (Meyerkord and Fu, 2015 , Modell et al., 2016 , Higueruelo et al., 2013b , Villoutreix et al., 2008 , Shoemaker et al., 2010 , R.Thangudu et al., 2012 ) for computational work-flow based on Shoemaker et al.((Shoemaker et al., 2010) )).
Once validated, compounds may provide start points to develop drug design strategies.
Modes of PPI modulation by compounds identified by PROTEINATOR
Despite of the large size of PPIs, small molecule modulators are known to be therapeutically effective ( (Arkin and Wells, 2004) ) (see ((Skwarczynska and Ottmann, 2015, Petta et al., 2016) ) for examples). PPI modulation by small molecules can be differentiated into four categories, each representing a distinct mechanism ( (Fischer et al., 2015) ) . Namely, compounds may affect interactions orthosterically or allosterically, and each of those may, in turn, stabilize ((Thiel et al., 2012) ) or disrupt the interfacial function or dynamics of the protein ( (Fischer et al., 2015) ) . There is a strong focus on targeting PPIs using small molecules in the recent years that has led to many successful drug discovery programs. This focus is driven by a strong rationale based on specific structural, biological and pharmacological basis. The motivation to develop this user interface to explore PPI modulators is driven by these principles, and are explained in the following sub-sections.
Orthosteric PPI modulation
Orthosteric binders are the majority class within the known small molecule PPI modulators, as indicated by the the large number of orthosteric inhibitors ((Fischer et al., 2015 , Arkin et al., 2014 ) . Orthosteric PPI modulators typically bind to the 'hot spot', in other words the most important side chains that constitute the interfacial binding site and majority contributors to the binding energy, thus disrupting/ stabilizing the PPI and/or the pathways they are constituents of. Stabilizers may bind to the rim of an established PPI, or may bind to one of the proteins to induce binding to a new protein ((Thiel et al., 2012) ) . PROTEINATOR provides a list of drugs that interact with a partner protein. Third party tools are required to check if the binding site is part of the interfacial surface (Ex. BioLiP((J. Yang et al., 2013)) https://zhanglab.ccmb.med.umich.edu/BioLiP), and thus influencing the interaction orthosterically. Further, researchers may also use PDBePISA( (Krissinel and Henrick, 2007) ) (http://www.ebi.ac.uk/pdbe/pisa/pistart.html), which provides a web-based service to evaluate the interacting surfaces using various theoretical approaches and strongly based on X-ray crystal structure data and representative of in silico approaches to explore druggable interfaces. Many techniques that score a PPI hotspot also exist and are reviewed before ((Fuller et al., 2009) ) . Once confirmed, the researcher may proceed with the validation or exploration using any of the techniques mentioned earlier. Researchers who are starting in this area can also use categorizations of the PPI targets of their interest based on structure ((Scott et al., 2016 , Raj et al., 2013 ) , and pick drug discovery strategies that may be more suited to the individual category.
Allosteric PPI modulation
Allosteric binders interact with the protein at a distal site, away from the PPI surface. They lock the protein in an altered conformation that may be a low-affinity conformation, resulting in allosteric inhibition, or a high-affinity conformation, resulting in allosteric stabalization. Allosteric sites are no different than canonical small-molecule binding sites, in contrast to the large untenable PPI interfaces ((Fuentes et al., 2009) ) . Hence, allosteric binders do not require to mirror large protein surfaces, but rather change the protein conformation to modulate the PPI. They are also much safer due to their specificity, non-competetive binding and the fact that they may not affect the protein if it is not in a bound state ((Nussinov and Tsai, 2014) ) (or in the context of this paper, the interacting state). It is reasonable to expect that PROTEINATOR will be most effective in exploring drugs that bind to an interacting protein to modulate the PPI allosterically, and consequently, the function of the protein of interest. This is based on the fact that most traditional drug discovery programs have not specifically targeted interfacial surfaces, but the drugs retreived may still alter the conformation and binding affinity of the protein. Typically any protein that displays a propensity for large conformational changes is a plausible target for allosteric modulation( (Arkin and Wells, 2004) ) . Our tool will most likely contribute to finding higher number of allosteric modulators simply because we do not search for compounds that only target interfacial surfaces, so the probability of the binding site being away from the protein-protein interface is much higher. Nearly all allosteric PPI modulators were discovered serendipitously ((Arkin et al., 2014) ) . Rational design or even a systematic search of allosteric modulators are challenging due to the fundamental structural complexity of proteins, but PROTEINATOR provides candidates that may be further explored since they are already known to inhibit one of the proteins, and based on the fact that the PPI is also validated. 
Methods

Data intergration, analytics and databases
Backend data processing
Pre-processed databases are stored in Hadoop Distributed File System ((Apache, 2018a)), and Apache Hive ( (Thusoo et al., 2009) ) is used to extract features required for this study. Apache Sqoop Apache ((2018b) ) was used to migrate relevant data to MySQL ((Oracle, 2018)), which is optimized for access through the web UI created using AngularJS ((AngularJS, 2018) ) and NodeJS ((Node.js, 2018) ) (see Supplemntary Material, S.4).
Case study
In this section we provide examples of how this tool may be used. Table 1 was produced by checking for specific proof in literature for the IBD use case (below), as well as randomly picking four more interactions to validate using literature. The exact procedure is outlined in Supplementary Material (S.1) .
1. The IBD (Inflammatory Bowel Disease) gene set: The genetics of IBD are complex, but there exist gene diagnostic panels that identify a set of genes based on principal loci associated with the diseases. Here, we have compiled a list of genes common to a few prominent diagnostic tool kits available, and identified drugs that may be used to modulate them (see Supplementary Material, S.1) .
PROTEINATOR allows the user to filter the results to ensure that there exists a common pathway between the two proteins, and this may be cross checked with common pathways to the disease of interest. While we did not manually verify all possible combinations, we have identified 3 highly plausible candidates (Eugenol, Dasatinib and Ruxolitinib) that can be repurposed to modulate 3 proteins (DKC1, FOXP3 and IL10) implicated in IBD through PROTEINATOR, and validated using literature (see Table 1 ).
2. The Cancer Proteome Atlas (TCPA) protein sets: TCPA( (Li et al., 2013) ) provides protein expression data sets for various cancers. The landing page provides an option to browse alternate leads to proteins that are significantly deferentially expressed (as determined by procedure outlined in S.2). We have provided the results of our exploration for plausible druggable proteins through indirect interactions for all TCPA datasets, which serves two purposes.
First, as a case study that shows potential users how to explore protein lists of their choice, and secondly, to highlight the results of drug repurposing based on DEPs (Differentially Expressed Proteins) present in TCPA across various cancer datasets. See Supplementary Material (S.5) for a detailed discussion.
Results
A comprehensive UI (see S.4 for description of usage) gives researchers the ability to identify 'indirect drugs' to proteins associated to disease. 112083 indirect interactions were found just using the drug-protein pairs found in Drug-Bank. Table 1 presents a set of 7 candidates that were 'found' through our tool. 3 of them were picked due to our interest in finding repositioning candidates for IBD, the others were chosen randomly to present utility of the tool and as a validation to the fact that there are many hits within this set of results that are worth exploring. PROTEINATOR comprises many start points for repurposing research, nonetheless filtering of false positives includes manual verification, which can then be further researched through experimental verification. In the IBD use case, 52 proteins of interest were identified to be studied via PRO-TEINATOR. While 12 of them were identified using our tool to have indirect drugs, 3 cases were verified using literature. AGain, this establishes the availability of many start points within the list that the tool provides. While these are interactions that are already identified and validated by the above mentioned literature, it can be extrapolated that our resource has many more interactions that can be explored.
Discussion
PROTEINATOR is a partial set of indirect drug interactions that have the possibility to modulate the protein of interest. It is expected that the existing set of 112083 plausible repurposing hypotheses will be enriched by adding other databases for each of the entities. Mechanisms through which repurposing candidates found by PROTEINATOR can modulate the primary protein indirectly through a drug binding protein are summarized below.
(1) Disrupting a PPI by directly binding to the interfacial surface (2) Disrupting a PPI by allosteric interference (3) Allosterically increasing the binding affinity to the protein partner (4) Stabalize PPI by direct binding to the interacting surface Recent studies ((Modos et al., 2017) ) show that neighbors of proteins implicated in cancer have a high degree of centrality in biological networks. They have clearly shown that first neighbor of cancer-related proteins have high local and global centrality in the network. Hence, additionally, our results will identify potential 'indirect' targets (and associated available drugs) through the discovery of interaction partners of proteins of interest, and provide an easy retrieval mechanism through the UI. The indirect targets and associated drug candidates that the web-based UI produces can be used by researchers to design wet-lab experiments seeking to discover therapeutic strategies that modulate their protein(s) of interest.
In effect, this addresses a major hurdle to target PPIs as drug targets, viz. the lack of start points to initiate a drug discovery programs, by providing existing drugs that target one of the protein partners. Just as in the use cases mentioned earlier, researchers have the possibility to focus on proteins of interest. The challenge of validating from an existing large set of hypotheses has to be overcome by scientific domain knowledge of the users and their biological system of interest. For validation, the users should consult published literature and use computational techniques like molecular dynamics to ascertain the disruption of PPI through the drug before wet lab-based experimentation. A P493-6 cell line is treated so as to drastically reduce proto-oncogene MYC expression, and
Ruxolitinib is used as a JAK inhibitor. It has been confirmed that JAK inhibition by Ruxolitinib effectively blocks the IL10-CpG synergism. This study directly implicates the triplet that PROTEINATOR introduces above.
4. GLI1 -IKBKB -Arsenic trioxide Chang et al.((Chang et al., 2016 ))
The study shows that Arsenic trioxide decreased the expression levels of GLI1 and thus proposes this as a promising new approach to treat lung cancer. While there no allusion to any allosteric relation, it clearly suggests an underlying mechanism which involves GLI1 blockade. Sierra et al. ((Sierra et al., 2018 ))
CXCL1 -EGFR -Gefitinib
The study provides direct evidence of reduced concentrations of chemokine CXCL11 in gastric tissues when treated with Gefitinib, in tandem with EGFR inhibition. They have use Luminexbased multiplex protein analysis. The study is across a low sample size due to unavoidable limitations, nonetheless, lower levels of soluble CD14 (p=0.007) were detected in patients with ulcerative colitis upon treatment with mesalazine, and as measured in plasma.
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